NanoViricides, Inc. Signs Agreement With Public Health England for Testing of Various NanoViricides Against Specific Viruses of Current Concern

Published: Jul 08, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") said it has signed a “confidential disclosure agreement” with Public Health England, the British government’s equivalent of the U.S. Centers for Disease Control. The agreement will allow the scientists at Public Health England to develop a specific proposal for the testing of different nanoviricides, such as FluCide®, against viruses of “mutual interest” to both organizations. More specifically, the first two viruses of mutual interest are H7N9, the influenza virus now circulating in China as well as the latest version of the coronavirus, now circulating in the Middle East. It is now referred to as the MERS virus. This virus is similar to the SARS virus that infected 8000 people and killed approximately 800 people 10 years ago. Both H7N9 and the MERS CoV (coronavirus) have extremely high case fatality rates. Testing of nanoviricides antiviral drug candidates will be performed in a BSL3/4 facility at PHE. BSL3/4 facilities are designed to contain and enable the safe handling of organisms that can pose a significant threat to health.

Help employers find you! Check out all the jobs and post your resume.

Back to news